Boston Scientific Stock Underperforms Market Amid Revised Guidance
Boston Scientific (BSX) has underperformed both the S&P 500 and healthcare sector ETFs over the past year, with its stock declining significantly. Despite better-than-expected Q1 2026 earnings, the company's revised guidance for the next quarter led to a 5.5% drop in its stock price on April 24, 2026.
Topics: Boston Scientific earnings guidance market sentiment S&P 500 stock performance